Doping and genetic testing: Sex difference in UGT2B15 expression, testosterone glucuronidation activity and urinary testosterone/epitestosterone glucuronide ratio

Current Pharmacogenomics and Personalized Medicine

Volumn 10, Issue 2, 2012, Pages 125-131

  Ekström, Lena ^a   Gök, Erdal ^b   Johansson, Maria ^a   Garle, Mats ^a   Rane, Anders ^a   Schulze, Jenny J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Androgens; Doping and genetic testing convergence; Legal and technology policy analysis; Sex difference; Sports medicine; T E ratio; Testosterone; UGT2B17

Indexed keywords

EPITESTOSTERONE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; TESTOSTERONE;

ARTICLE; ATHLETE; CONTROLLED STUDY; DOPING; ENDURANCE SPORT; FEMALE; GENDER AND SEX; GENE DELETION; GENE EXPRESSION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GLUCURONIDATION; HEALTH CARE POLICY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDEL MUTATION; LIVER MICROSOME; MALE; MEDICOLEGAL ASPECT; PERSONALIZED MEDICINE; SEX DIFFERENCE; TESTOSTERONE METABOLISM;

EID: 84861746542     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569212800626403     Document Type: Article

References (40)

1. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
2. Levesque E, Turgeon D, Carrier JS, et al. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 2001; 40(13): 3869-81.
3. Belanger A, Pelletier G, Labrie F, et al. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab 2003; 14(10): 473-9.
4. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003; 3(3): 136-58.
5. Labrie F, Belanger A, Cusan L, et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997; 82(8): 2403-9.
6. Turgeon D, Carrier JS, Levesque E, et al. Relative enzymatic activity, protein stability, and tissue distribution of human steroidmetabolizing UGT2B subfamily members. Endocrinology 2001; 142(2): 778-87.
7. Turgeon D, Carrier JS, Levesque E, et al. Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J Mol Biol 2000; 295(3): 489-504.
8. Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y (268) and UGT2B7H(268). Drug Metab Dispos 1998; 26(1): 73-7.
9. Sten T, Bichlmaier I, Kuuranne T, et al. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab Dispos 2009; 37(2): 417-23.
10. Beaulieu M, Levesque E, Tchernof A, et al. Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol 1997; 16(10): 1143-54.
11. Guillemette C, Levesque E, Beaulieu M, et al. Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 1997; 138(7): 2998-3005.
12. Belanger A, Hum DW, Beaulieu M, et al. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol 1998; 65(1-6): 301-10.
13. Anderson GD. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. J Gend Specif Med 2002; 5(1): 25-33.
14. Gallagher CJ, Balliet RM, Sun D, et al. Sex differences in UDPglucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos; 38(12): 2204-9.
15. Wilson W, 3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84(4): 707-14.
16. Xue Y, Sun D, Daly A, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet 2008; 83(3): 337-46.
17. Jakobsson J, Ekstrom L, Inotsume N, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91(2): 687-93.
18. Schulze JJ, Lundmark J, Garle M, et al. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab 2008; 93(7): 2500-6.
19. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf [Accessed Feb 12, 2012]
20. Chung BC, Choo HY, Kim TW, et al. Analysis of anabolic steroids using GC/MS with selected ion monitoring. J Anal Toxicol 1990; 14(2): 91-5.
21. Garle M, Ocka R, Palonek E, et al. Increased urinary testosterone/epitestosterone ratios found in Swedish athletes in connection with a national control program. Evaluation of 28 cases. J Chromatogr B Biomed Appl 1996; 687(1): 55-9.
22. Schaeffeler E, Schwab M, Eichelbaum M, et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003; 22(6): 476-85.
23. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999; 14(5-6): 143-9.
24. von Bahr C, Groth CG, Jansson H, et al. Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin Pharmacol Ther 1980; 27(6): 711-25.
25. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193(1): 265-75.
26. Narayanan R, LeDuc B, and Williams DA. Determination of the kinetics of rat UDP-glucuronosyltransferases (UGTs) in liver and intestine using HPLC. J Pharm Biomed Anal 2000; 22(3): 527-40.
27. Schulze JJ, Lorentzon M, Ohlsson C, et al. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes. Pharmacogenet Genomics 2008; 18(6): 477-85.
28. Chouinard S, Pelletier G, Belanger A, et al. Isoform-specific regulation of uridine diphosphate-glucuronosyltransferase 2B enzymes in the human prostate: differential consequences for androgen and bioactive lipid inactivation. Endocrinology 2006; 147(11): 5431-42.
29. Owen R and Goldberg N. Responsible innovation: a pilot study with the U.K. Engineering and Physical Sciences Research Council. Risk Anal 2010; 30(11): 1699-707.
30. The UNESCO Convention. Available from: http://unesdoc.unesco. org/images/0014/001425/142594m.pdf#page=2 [Accessed Feb 29, 2012]
31. Copenhagen Declaration. Available from: http://www.wada-ama. org/Documents/World_Anti-Doping_Program/Governments/WADA_Copenhagen_Declaration_EN.pdf [Accessed Feb 12, 2012]
32. The WADA Code. Available from: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-The-Code/WADA_Anti-Doping_CODE_2009_EN.pdf [Accessed Feb 12, 2012]
33. The Charter of the IOC. Available from: http://www.olympic.org/Documents/olympic_charter_en.pdf [Accessed Feb 12, 2012]
34. Gallagher CJ, Balliet RM, Sun D, et al. Sex differences in UDPglucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos 2010; 38(12): 2204-9.
35. Chen G, Giambrone NE, Jr., Dluzen DF, et al. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res 2010; 70(19): 7543-52.
36. Balliet RM, Chen G, Gallagher CJ, et al. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009; 69(7): 2981-9.
37. Ayotte C. Detecting the administration of endogenous anabolic androgenic steroids. Handb Exp Pharmacol 2010; (195): 77-98.
38. Schulze JJ, Lundmark J, Garle M, et al. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids 2009; 74(3): 365-8.
39. Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol Metab Clin North Am 2010; 39(1): 59-73, viii-ix.
40. Sottas PE, Robinson N, Rabin O, et al. The athlete biological passport. Clin Chem 2011; 57(7): 969-76.